SAMSUNG PHARM. Co., LTD. announced that it has received KRW 10.2 billion in funding from a group of investors
February 05, 2017
Share
Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) announced a private placement of 28th series unregistered coupon unguaranteed unsecured private convertible bonds for gross proceeds of KRW 10,200,000,000 on February 6, 2017. The transaction included participation from 24 investors, including existing investor Aju Savings Bank, Investment Arm for KRW 4,000,000,000, Shm Co.,Ltd for KRW 1,100,000,000, Sequoia Investments Ltd. for KRW 1,000,000,000, and 21 individual investors. The bonds will mature on February 6, 2020. The zero coupon bonds carry yield to maturity of 4%. The bonds can be 100% convertible into common shares at a fixed conversion price of KRW 4,102 per share from February 6, 2018 to January 6, 2020. The bonds were issued at par. The transaction has been approved by the board of directors of the company.
SAMSUNG PHARM. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. The Pharmaceutical and Quasi-drug Sale Business segment manufactures and sells prescription medicines, general pharmaceuticals and quasi-medicines. This segment's products include anticancer immunotherapy agents, antipyretic analgestic and anti-inflammatory agents, hypotensive agents, antiarteriosclerotic agents, anti-spastics, enzyme agents, ostepoposis agents, antibiotics, medicines for digestive system, medicines for liver disorder, medicines for circulation system and vitamin supplements, among others. The Health Food Manufacturing and Sale segment manufactures and sells nutrition and invigoration products.